GlassScriptPhysician profile
Sandra M Cox
NPI 1447541883
$5,251.22
in general payments reported to CMS, 2019-2025
34 companies · $737 in 2025
The $737 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,805 · 2022: $1,422 · 2023: $1,265 · 2024: $21.23 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792 · Long Term Medical Supply Or Device Loan: $167 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.11 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,197.70 | 2021-2025 | |
| Janssen Biotech, INC. | $390.80 | 2021-2025 | Darzalex, Erleada, Tecvayli |
| Novocure INC. | $337.01 | 2025 | Optune Lua (Novottf-200t) |
| Glaxosmithkline, LLC. | $311.49 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| E.R. Squibb & Sons, L.L.C. | $245.19 | 2023 | Opdivo, Reblozyl, Opdualag |
| Eisai INC. | $217.65 | 2021-2023 | |
| Astellas Pharma US INC | $198.95 | 2021-2022 | |
| Seagen INC. | $151.63 | 2023 | Tukysa |
| Merck Sharp & Dohme LLC | $132.79 | 2021-2025 | Keytruda, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $117.21 | 2022-2023 | |
| Abbvie INC. | $101.51 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $85.33 | 2021-2023 | Epkinly |
| Kite Pharma, INC. | $76.19 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $67.49 | 2021-2023 | Onivyde |
| Gilead Sciences, INC. | $64.85 | 2022-2023 | Trodelvy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $60.09 | 2022-2023 | Braftovi, Lorbrena, Mektovi |
| Aveo Pharmaceuticals, INC. | $58.23 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $44.31 | 2023 | Tecvayli, Darzalex |
| Taiho Oncology, INC. | $41.94 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $41.67 | 2021-2022 | |
| Daiichi Sankyo INC. | $40.09 | 2022-2025 | Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $39.29 | 2023 | |
| Pfizer INC. | $28.60 | 2021-2025 | |
| Tersera Therapeutics LLC | $26.23 | 2022 | |
| Organogenesis INC. | $21.23 | 2024 | |
| Amgen INC. | $19.87 | 2023 | Kyprolis, Blincyto |
| Genzyme Corporation | $19.78 | 2025 | |
| Dova Pharmaceuticals | $19.33 | 2021 | |
| Geron Corporation | $18.54 | 2025 | Rytelo |
| Lilly USA, LLC | $17.84 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.06 | 2022 | |
| Celgene Corporation | $15.37 | 2023 | Reblozyl |
| Janssen Pharmaceuticals, INC | $14.21 | 2022 | |
| Blueprint Medicines Corporation | $12.75 | 2023 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.